会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
    • 抑制NHE介导的抗生素治疗与流体滞留,盐负荷过重和胃肠道病变相关的疾病的化合物和方法
    • WO2010078449A3
    • 2010-09-30
    • PCT/US2009069852
    • 2009-12-30
    • ARDELYX INCCHARMOT DOMINIQUEJACOBS JEFFREY WLEADBETTER MICHAEL ROBERTNAVRE MARCCARRERAS CHRISBELL NOAH
    • CHARMOT DOMINIQUEJACOBS JEFFREY WLEADBETTER MICHAEL ROBERTNAVRE MARCCARRERAS CHRISBELL NOAH
    • C07C311/29A61K31/18A61K31/472A61K31/4725A61K31/517A61K31/662A61K31/675A61K45/06C07D217/04C07D401/12C07F9/38C07F9/40C07F9/572C07F9/62
    • A61K31/4725A61K31/18A61K31/472A61K31/517A61K31/662A61K31/675A61K45/06C07C311/29C07D215/14C07D217/04C07D217/14C07D217/16C07D401/12C07F9/3808C07F9/3834C07F9/3882C07F9/5765C07F9/60C07F9/65583
    • The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.
    • 本公开涉及用于治疗与体液潴留或盐超负荷相关的病症例如心力衰竭(特别是充血性心力衰竭),慢性肾病,终末期肾病,肝病和过氧化物酶体的化合物和方法 增殖激活受体(PPAR)γ激动剂诱导的液体潴留。 本公开还涉及用于治疗高血压的化合物和方法。 本公开还涉及用于治疗胃肠道病症的化合物和方法,包括治疗或减轻与胃肠道病症相关的疼痛。 所述方法通常包括向需要其的哺乳动物施用药物有效量的化合物或包含该化合物的药物组合物,其被设计为在胃肠(GI)道中基本上具有活性以抑制NHE介导的钠 离子和氢离子。 更特别地,所述方法包括向需要其的哺乳动物施用药学有效量的化合物或包含该化合物的药物组合物,其抑制NHE-3,-2和/或-8介导的钠和/或 氢气离子在胃肠道中,并被设计为对上皮细胞层,或更具体而言,胃肠道的上皮层基本上不可渗透。 由于该化合物基本上不可渗透,所以它不被吸收,因此基本上不具有生物可利用性,从而限制其它内部器官(例如肝脏,心脏,脑等)暴露于其中。 本发明还进一步涉及一种方法,其中将哺乳动物与流体吸收聚合物一起给予这种化合物,使得所述组合如上所述起作用并进一步提供螯合存在于胃肠道中的流体和/或盐的能力 。